focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
definitely there are loads in the red and not just CINE.
Bloomberg had a headline news mentioning about end of quarter and profit taking.
Most likely tomorrow will be blue for all that are down today.
went through at 78p around 11.45
Some good 20K buys went through as well.
Good Morning/Afternoon LPD & Mountainous, hope you are well. Yes, I too can see my local cinema filling up nicely. Although not all shows are 100% full and likewise some are not completely empty either. They are running Bond almost every 30mins-1hr!
Today's drop is nothing to do with Cine specific news. LIke someone said, end of the quarter so some profit taking going on.
Polaris would not increase their stake if they don't believe in the way court case is going. They could have otherwise waited until the outcome. They too must have realised the potential once the last headwind is cleared.
LIke I said Bond news over the weekend will setup a good start for next week.
nonsense is saying £1 a fair value!
By XMas this will be back to 130p. Market cannot ignore all the advertisement for XMas and there is no way retailers would stay away from ITV to advertise their products.
If C4 acquisition is not materialising then I expect a special dividend announcement from ITV.
few steps back for the next jump. If you panic sell then you will be buying at a higher price. You cannot time the market to catch bottom. Keep powder dry.
Polaris increased their stake just last week. It is not for selling it today in a week.
Weekend there will be more good news about Bond and that should help setup for the jump next week.
Couple of thigs -
- They wouldn't do a Q&A if they think that trials are not going well. They can simply RNS the results may be? They are not obliged to do Q&A.
- In that FT article, one of the author said, even if the antiviral is 40% effective, that is brilliant but SNG's is fully effective based on P2.
My only worry is that I have seen pharmas where the product had successful P3 trials but commercialisation took ages whereas in SNG case, world needs it so get that P3 successful and we should be flying towards that £10.
missed NCYT rise to £14 but not missing this one.
what a load of ****.
I was right with my 80p forecast but you were mocking me with that forecast. I clearly posted the link about £1.50 target price from Jefferies and it is not my finger in the air prediction but you dumb head still don't get it.
If you stop disrupting this board every hour and every day then there will be lot more research that gets posted but you can't resist without a dog fight every day.
You blamed your friend when you got it wrong with the RNS and that shows what a **** piece you are.
All your posts are only worth a big yawn. Nothing else but utter garbage. I have filtered you for good.
It is best for everyone to filter this clown and don't reply to him. Waste of our time.
about their increase is quite comforting to me. They too seem to believe that CINE was in oversold territory until last week.
Not only Bond but we have several big box office movies coming in next few months and from next year too. They must have figured out that all the headwinds that CINE was facing are clearing up. Once cineplex is sorted, am expecting a rapid rise to £1+
Last night I have reviewed all their loan maturity dates too and all of them are due to mature starting from 2024, which means the interest rate is locked in. There is only B1 Term loan that has high interest payment and the loan secured on that is around $500M. I'm sure that Mooky will target that amount to pay it off first or atleast reduced it as much as possible. Rest all are at reasonable 7-8% range. Now the thing is that once Mooky starts to pay the debt, the bond holders might consider converting their warrants to equity and one of the convertible warrants price is at £1.26!!!
We will see £1.20 in not very distant future.
The big box office movies including TopGun next year and many more that are coming in next 18 months could easily take our SP back to pre-covid levels.
Now Bonkers, can you try putting your own research work? Never seen in any of your posts.
It is called Newton's 3rd law. For every action there will be an equal and opposite reaction :-)
"However while bond is having a nice impact on the s.p I personally can't see it being responsible for nearly a 100% rise.
Let's hope im wrong , but s.p forcast is effectively just a guessing game on here.
"
You may be proved wrong just like how you and Wellington got wrong mocking 80p by bond release.
Jefferies have £1.50 target on CINE. We are close to £1. We may sit at £1.20 easily by December.
However, Eric Topol, director of the California-based Scripps Research Translational Institute, said that, provided antivirals were “highly effective and safe, and inexpensive or provided freely, I think they will be quite widely used”. This would particularly apply if the treatment was available as “a pill, oral route medication or an inhalation as opposed to an injection under the skin”, he added.
What have trials shown?
Although multiple Covid vaccines have been authorised, US group Gilead’s infusion remdesivir, which is administered intravenously, is the only antiviral treatment that has been approved by the US Food and Drug Administration (FDA) — despite its uncertain benefit to patients. Scientists at the World Health Organization say the drug has “no meaningful effect” on mortality or the need for ventilation.
Kartsonis at Merck said antiviral drugs must first be studied, and the correct dose calculated, on healthy individuals before being trialled on Covid-19 patients. That, he said, partly explained why only one antiviral treatment had been approved.
He noted that antivirals must be absorbed, metabolised and excreted correctly but vaccine makers “don’t have to worry about those other characteristics because they don’t really apply”.
In Europe, Swiss pharma company Roche is working with Atea Pharmaceuticals on an oral antiviral it believes has dual potential: to treat people with Covid-19 and prevent illness in people who have been exposed to the virus.
Initial results in hospitalised patients with moderate Covid-19 and at high risk of poor outcomes “indicated a rapid and sustained antiviral activity against Sars-Cov-2, with no new or unexpected safety results”, the company said.
What role are governments playing?
In June, the US unveiled plans to invest $3bn in antiviral drug development, saying it would help create the next generation of coronavirus treatments.
The funding will be spent on accelerating clinical trials of antiviral drugs and the creation of a new Antiviral Drug Discovery centre to develop treatments for as yet unidentified coronaviruses in order “to better prepare the nation for future viral threats”.
Joe Biden’s administration also signed a $1.2bn deal with Merck in June for 1.7m courses of molnupiravir if the tablet received approval from the FDA.
In April Boris Johnson, UK prime minister, established an antivirals task force, modelled on the country’s successful vaccines task force.
He pledged “to have at least two effective treatments this year, either in a tablet or capsule form” that could be taken at home following a positive test or exposure to someone with the virus. But as yet there has been no word from the task force and its leader, pharmaceutical industry veteran Eddie Gray, on whether that target will be met.
The UK health department said there were “a number of exciting opportunities in the pipeline” and promised to provide “further details in due course”.
Antiviral pill: How close are we to a drug to treat Covid?
Who is working on them?
Merck’s tablet, called molnupiravir, would be taken within five days of Covid-19 symptoms emerging, twice a day for five days. It is in phase-3 trials and the company expects to have data by the end of this year. Merck has also started household trials of molnupiravir in people who do not have coronavirus but are living with someone who does.
US pharmaceutical group Pfizer is also carrying out late-stage trials of its antiviral tablet. The company is studying two antivirals — a tablet that can be taken at home and an intravenous infusion for patients suffering from more serious disease. The medicines work by blocking the activity of the Covid protease, an enzyme that the virus needs in order to replicate in the body.
An inhaled interferon treatment being produced by a UK drug discovery company, Synairgen, has also emerged as a potentially promising approach to treating the disease.
Richard Marsden, the company’s chief executive, said one of the main ways viruses evaded the immune system was “to suppress the production of interferon beta”, which plays a significant role in activating the wider immune response and preventing a virus from replicating. “All we’re doing is putting?.?.?.?this protein, that everyone makes, back into the battleground, and the battleground that matters is in the lungs,” added Marsden.
Who would receive antiviral drugs?
Recipients might include immunosuppressed people for whom Covid-19 vaccines do not work, or a defined group — such as a school, care home or football team — in which they could be used prophylactically to forestall a wider outbreak.
The trick, however, would be timing as such products needed to be given at the first sign of symptoms, said Steve Bates, chief executive of the UK’s BioIndustry Association.
Bates said he would be “unsurprised” to see at least one antiviral drug ready to be rolled out in the coming weeks, potentially under an “emergency use authorisation”, through which products yet to win full regulatory approval can be made available during a public health crisis.
But Bates, a former member of Britain’s vaccines task force, suggested mass deployment across the UK population was unlikely.
“I think of them as more specialist tools, probably used in particular groups of the population or at a particular point in an outbreak,” he added.
People may have to adjust their expectations of how transformative this category of medicines will be.
Efficacy levels might be far lower than the public had come to expect from the vaccines, Bates warned. “Because of this problem of when you administer them, it’s almost impossible to get a really good result statistically. And if you get an antiviral that works at 40 per cent, I think that will be brilliant,” he said.
Jep & Eileen, you both are wasting your time talking about Tesla valuation. This talk has been going on since last year when share price was $500. From $500, it has gone up to nearly $4000 (if there was no split of shares). Now that itself should teach you something that market loves Tesla. From the current valuation to do a multiple, it may not happen anytime soon but the price is not going to drop from here to any lows that you both are expecting.
DB has been patient replying all the technicals but you both are easily discarding the technicals and always coming back with the valuation and profit margins. Do you think only you 2 and Mr. Bury are the cleverst and think can bring Tesla down. It is not going to happen!
You can compare Tesla to Apple in mobile phone market. There were so many models but Apple still is the one that people want. Of course with cars, there are so many beautiful models out there when compared to Tesla but when you look at the market dominance, Tesla is in the top in many regions and in other regions in Top 3. Take a look at NIO, it was compared to be biggest competitor and now see what happened to its share price. Polestar SPAC? If you believe in that SPAC then go and invest but I can assure you that there will not be any demand for their shares. VW CEO warns that electric transition impossible to accelerate due to chip shortage. That is an excuse to cover the sales drop. Tesla still delivered beyond the estimates despite chip shortage.
Tesla brand has immense popularity due to E.Musk. No one wants to buy a compact ID3 or infact any BMW or Audi as people are bored of seeing these names and even electric models are shaped in traditional way. People want something new when they are spending their money and Tesla is the new name, which everyone wants. Doesn't matter how Tesla looks like. People feel luxurious buying a Tesla.
Just go to a Tesla showroom and feel for yourself. I for one do not have a Tesla but when I want to buy electric vehicle then surely it will be Tesla.
Today Tesla closed at $791!!! It looks like it is heading to that $900 figure. Now imagine if Tesla announces a stock split again! It will go crazy!!! NVIDIA did it when the price hit $800. I hope Elon does one more stock split! GLA
Definitely next 3 months there will be lot of advertising money that ITV will make. Also the tariffs for ads would have increased compared to precovid.
Big money will come back here. Just need more patience. I think results in Oct/Nov should look better.
I would say Bond news is still not priced in! Once the Bond figures come in, this is going to head much higher.
Polaris must have increased holdings in at around 67p last week and they are going to wait atleast until Mooky gets his bonus at £1.90.
Fair value is £1.50 as per Jefferies target. That is where this is heading to.
Agreed Antmoss.
Happy to retract my comments.
GL to Popeye and D9.
Popeye, where are you mate? Mocked me for 80p prediction? Not that am claiming to be right for prediction but that guy bought at 61p or so and sold it off and then later started de-ramping CINE.
Btw, where is dumb Dragon? If he is clever like he claims then that short he has should have been closed off in the morning.
Enjoying the rise! Good job everyone for holding strong and supporting CINE with your investments. We will see £1 at some point so hold on to your shares.
This indeed is a game changer. I read an article last week about Vertical Aerospace(VA) bagged a multi million order from Japan for about 150 Air Taxis and I wasn't aware until now that VA's electric engines are powered by RR -
https://www.rolls-royce.com/products-and-services/electrical/propulsion/air-taxis.aspx
I was looking at how to invest in VA but when RR is powering them up why go elsewhere! Thank you for saving my time in research. With RR's investment in Electric, we are in a very good shape. I'm hoping that with all this technology advancements, in couple of years time, price will be many multiple times than the current price. I suggest do not bother to look at the price for couple of years. Doesn't matter going with all eggs in one basket with RR!
Fantastic rise.
Sorry LPD. That will be my last post on the topic.
I want to read Sunday times article. Looks like media is changing their opinion now on cinemas.
It looks like we are heading to 80p by next weekend. Let's see how soon we get there.